Inicio › Trastorno depresivo mayor › Connecticut
Ensayos clínicos de Trastorno depresivo mayor en Connecticut
15 estudios sobre Trastorno depresivo mayor buscan participantes en Connecticut.
Ciudades en Connecticut
Texto oficial del estudio (inglés)
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Yale School of Medicine - Yale Program for Psychedelic Science, New Haven
ReclutandoFase 3
Edades de 18 a 85 · Todos los sexos · Actualizado el 13 nov 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Cromwell
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 10 nov 2026 · NCT07065240A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Yale University School of Medicine, New Haven
ReclutandoFase 3
Edades de 18 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT07412756Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- UConn Health Center, Farmington
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 3 nov 2026 · NCT06559306A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Yale Child Study Center, New Haven
ReclutandoFase 3
Edades de 12 a 17 · Todos los sexos · Actualizado el 3 nov 2026 · NCT07227454Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- University of Connecticut Health Center, Farmington
ReclutandoFase 3
Edades de 18 a 65 · Todos los sexos · Actualizado el 3 nov 2026 · NCT05850689Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cromwell
- Neurocrine Clinical Site, Farmington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06966401Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- CT Clinical Research, Cromwell
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 28 oct 2026 · NCT07226661A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, New Haven
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT07196501Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- University of Connecticut School of Medicine Psychiatry Department, Farmington
ReclutandoFase 2
Edades de 18 a 64 · Todos los sexos · Actualizado el 3 ago 2026 · NCT06547489The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- VA Connecticut Healthcare System, West Haven
ReclutandoFase 2
Edades de 21 a 65 · Todos los sexos · Actualizado el 6 may 2026 · NCT05786066Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Yale University, New Haven
ReclutandoFase 1
Edades de 18 a 60 · Todos los sexos · Actualizado el 6 may 2026 · NCT05915013Imaging Depression in Parkinson's Disease
- Yale University, New Haven
ReclutandoFase 2Se aceptan voluntarios sanos
Edades de 40 a 80 · Todos los sexos · Actualizado el 10 mar 2026 · NCT06402955Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- Hartford Hospital, Hartford
ReclutandoEstudio observacional
Edades de 18 a 40 · Todos los sexos · Actualizado el 10 mar 2026 · NCT06740383Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #122, Cromwell
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 20 ene 2026 · NCT06633016De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.